Level of knowledge about dyslipidemia screening in clinical laboratories in Portoviejo, Ecuador
DOI:
https://doi.org/10.36097/rgcs.v3i1.3221Keywords:
dyslipidemias, primary dyslipidemias, diagnosis strategy for dyslipidemiasAbstract
Dyslipidemias are associated with the atherosclerotic process, and it has been shown that the control of these alterations reduces the incidence of episodes of ischemic origin. The purpose of this research was to assess the level of knowledge about the diagnosis of dyslipidemia according to international recommendations and strategies, through a survey of health personnel involved both in performing the tests and in the indication of the study of dyslipidemia. A total of 60 people were surveyed, more than half were in their second decade of life, and a little less than half had less than a year of work experience. The majority were laboratory technicians and doctors, but very few had fourth-level studies. More than half practiced their profession in different health centers in the province of Manabí, and some teachers and students from the Faculty of Health Sciences of the Manabí Technical University participated. The respondents had levels of knowledge valued from medium to low when they were consulted about the basic lipid profile for the correct diagnosis of it, about the concept of atherogenic cholesterol (non-HDL), about the users to whom the profile should be measured lipid as a screening test and on the conditions that affect the pre, post and analytical phases of the lipid profile.
Downloads
References
Candás, B., Pocoví, M., Romero, C., Vella, J. C., Esteban, M., Castro, M. J., Rodríguez, E., Arrobas, T., Calmarza, P., & Puzo, J. (2019). Estrategia para el diagnóstico de las dislipidemias: Recomendación 2018. Revista del Laboratorio Clínico, 12(4), e21-e33. https://doi.org/10.1016/j.labcli.2019.03.001
Carrillo-García, C., Solano-Ruíz, M. del C., Martínez-Roche, M. E., & Gómez-García, C. I. (2013). Influencia del género y la edad en la satisfacción laboral de profesionales sanitarios. Revista Latino-Americana de Enfermagem, 21(6). https://doi.org/10.1590/0104-1169.3224.2369
Cholesterol Treatment Trialists’ Collaboration. (2019). Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet, 393(10170), 407-415. https://doi.org/10.1016/S0140-6736(18)31942-1
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., Evans, S., Law, M., MacMahon, S., Martin, S., Neal, B., Poulter, N., Preiss, D., Ridker, P., Roberts, I., Rodgers, A., Sandercock, P., Schulz, K., Sever, P., Simes, J., Smeeth, L., Wald, N., Yusuf, S., & Peto, R. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. The Lancet, 388(10059), 2532-2561. https://doi.org/10.1016/S0140-6736(16)31357-5
Díaz, L., & García, A. (2013). Guía de tratamiento farmacológico de dislipidemias para el primer nivel de atención. Revista Mexicana de Cardiología, 24(3), 103-129. http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0188-21982013000300001
Díaz-Toro, Felipe, Nazzal Nazal, Carolina, Verdejo, Hugo, Rossel, VÍctor, Castro, Pablo, Larrea, Ricardo, Concepción, Roberto, & Sepúlveda, Luis. (2017). Factores asociados a fragilidad en pacientes hospitalizados con insuficiencia cardiaca descompensada. Revista Médica de Chile, 145(2), 164-171. https://dx.doi.org/10.4067/S0034-98872017000200003
Endalamaw, A., Khatri, R. B., Erku, D., Zewdie, A., Wolka, E., Nigatu, F., & Assefa, Y. (2024). Barriers and strategies for primary health care workforce development: Synthesis of evidence. BMC Primary Care, 25(1), Article 99. https://doi.org/10.1186/s12875-024-02336-1
Escobar, C., Soto, V., Pacheco, N., & Barros, T. (2022). Asociación de factores de riesgo cardiovascular modificables y la capacidad cardiovascular en población universitaria de 18 a 29 años. Revista de la Facultad de Ciencias Médicas (Quito), 47(1), 25-34. https://doi.org/10.29166/rfcmq.v47i1.2973
Esteban, M., Aguilar, J. A., Gómez, J. A., Romero, C., Castro, M. J., Calmarza, P., Arrobas, T., & Candás, B. (2013). Lipoproteína (a): Factor de riesgo emergente de enfermedad cardiovascular. Sociedad Española de Bioquímica Clínica y Patología Molecular. Comisión de Lipoproteínas y Enfermedades Vasculares. https://bit.ly/4rceLjT
Gallardo, W. D., & García, M. A. (2024). Junk food: analysis of risks, benefits, and social perception. Journal of Food Science and Gastronomy, 2(1), 26-34. https://doi.org/10.5281/zenodo.13996283
Goff, D. C., Jr., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., Robinson, J. G., Schwartz, J. S., Shero, S. T., Smith, S. C., Jr., Sorlie, P., Stone, N. J., Wilson, P. W., Jordan, H. S., Nevo, L., Wnek, J., Anderson, J. L., Halperin, J. L., Albert, N. M., Bozkurt, B., Brindis, R. G., Curtis, L. H., DeMets, D., Hochman, J. S., Kovacs, R. J., Ohman, E. M., Pressler, S. J., Sellke, F. W., Shen, W. K., Tomaselli, G. F., & American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129(25, Suppl. 2), S49-S73. https://doi.org/10.1161/01.cir.0000437741.48606.98
Guallar-Castillón, P., Gil-Montero, M., León-Muñoz, L. M., Graciani, A., Bayán-Bravo, A., Taboada, J. M., Banegas, J. R., & Rodríguez-Artalejo, F. (2012). Magnitud y manejo de la hipercolesterolemia en la población adulta de España, 2008–2010: El estudio ENRICA. Revista Española de Cardiología, 65(6), 551-558. https://doi.org/10.1016/j.recesp.2012.02.005
Lobos, J. M., Galve, E., Royo-Bordonada, M. Á., Alegría, E., Armario, P., Brotons, C., Camafort, M., Cordero, A., Maiques, A., Mantilla, T., Pérez, A., Botet, J. P., Villar, F., & González-Juanatey, J. R. (2014). Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemias: Divergencia entre las guías europea y estadounidense. Revista Española de Cardiología, 67(11), 913-919. https://doi.org/10.1016/j.recesp.2014.05.008
Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., Chapman, M. J., Cobbaert, C., Descamps, O. S., von Eckardstein, A., Kamstrup, P. R., Pulkki, K., Kronenberg, F., Remaley, A. T., Rifai, N., Ros, E., & Langlois, M., en nombre de la European Atherosclerosis Society y la European Federation of Clinical Chemistry and Laboratory Medicine. (2016). Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points—A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 37(25), 1944-1958. https://doi.org/10.1093/eurheartj/ehw152
Organización Panamericana de la Salud [OPS]. (2020). Enfermedades cardiovasculares. https://www.paho.org/es/temas/enfermedades-cardiovasculares
Pedro-Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Hernández-Mijares, A., Pintó, X., Millán, J., & Grupo de Trabajo sobre Dislipidemia Aterogénica de la Sociedad Española de Arteriosclerosis. (2020). Triglicéridos, colesterol HDL y dislipidemia aterogénica en la guía europea para el control de las dislipidemias 2019. Clínica e Investigación en Arteriosclerosis, 32(5), 209-218. https://doi.org/10.1016/j.arteri.2019.12.003
Pedro-Botet, J., Rodríguez-Padial, L., Brotons, C., Esteban-Salán, M., García-Lerín, A., Pintó, X., Lekuona, I., & Ordóñez-Llanos, J. (2018). Homogenization of the lipid profile values. Clinical Investigation in Arteriosclerosis, 30(1), 36-48. https://doi.org/10.1016/j.arteri.2017.12.001
Pencina, M. J., Navar-Boggan, A. M., D’Agostino, R. B., Sr., Williams, K., Neely, B., Sniderman, A. D., & Peterson, E. D. (2014). Application of new cholesterol guidelines to a population-based sample. The New England Journal of Medicine, 370(15), 1422-1431. https://doi.org/10.1056/NEJMoa1315665
Pozo, C. (2016). Frecuencia de dislipidemia en trabajadores de la industria de la Ciudad de Quito noviembre 2015 - enero 2016 [Bachelor thesis, Universidad Central del Ecuador]. http://www.dspace.uce.edu.ec/handle/25000/6811
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., Sever, P. S., Pedersen, T. R., & FOURIER Steering Committee and Investigators. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. The New England Journal of Medicine, 376(18), 1713-1722. https://doi.org/10.1056/NEJMoa1615664
Sabatine, M. S., Wiviott, S. D., Im, K., Murphy, S. A., & Giugliano, R. P. (2018). Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: A meta-analysis. JAMA Cardiology, 3(9), 823-828. https://doi.org/10.1001/jamacardio.2018.2258
Segura, L., Agusti C., R., & Ruiz, E. (2013). Factores de riesgo de las enfermedades cardiovasculares en el Perú II: Estudio TORNASOL II comparado con TORNASOL I después de cinco años. Revista Peruana de Cardiología, 39(1), 5-59. https://repebis.upch.edu.pe/articulos/rpc/v39n1/a1.pdf
Uribe-Risco, V. A., Holguín-Pilligua, J. L., Valero-Cedeño, N. J., & Yépez-Martínez, J. M. (2020). Prevalencia de dislipidemias en pacientes de la zona sur de Manabí, provincia de Manabí-Ecuador. Polo del Conocimiento, 5(5), 520-539. https://doi.org/10.23857/pc.v5i6.1509
Vaucher, J., Marques-Vidal, P., Preisig, M., Waeber, G., & Vollenweider, P. (2014). Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease. European Heart Journal, 35(15), 958-959. https://doi.org/10.1093/eurheartj/ehu064
Warnick, G. R., Kimberly, M. M., Waymack, P. P., Leary, E. T., & Myers, G. L. (2008). Standardization of measurements for cholesterol, triglycerides, and major lipoproteins. Laboratory Medicine, 39(8), 481-490. https://doi.org/10.1309/6UL9RHJH1JFFU4PY
Published
Data Availability Statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Issue
Section
License
Copyright (c) 2026 Aron R. Zamora, Katiuska K. Chávez, Danny X. Narváez, Ivón Howland
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
